Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

rozanolixizumab 10zilucoplan 7ravulizumab 7efgartigimod alfa 6eculizumab 5fludarabine 4Cyclophosphamide 4telitacicept 3Tacrolimus 3HBM9161 3inebilizumab 2Mycophenolic Acid 2Diagnostic Self Evaluation 2Amifampridine 2satralizumab 1rhoA GTP-Binding Protein 1remibrutinib 1iscalimab 1iptacopan 1Robotic Surgical Procedures 1Prednisone 1Prednisolone 1Plasmapheresis 1Immunoglobulins, Intravenous 1Data Collection 1Cladribine 1CK-2017357 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Myasthenia Gravis × Cladribine × Clear all
NCT06463587 2026-05-22

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3 Recruiting
264 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡